Verve Therapeutics

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan and Burt A. Adelman in 2018 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer and Andrew Bellinger, M.D., Ph.D., chief scientific officer and chief medical officer, will participate in a fireside chat during the Jefferies Gene Therapy/Editing Summit on Thursday, October 28, 2021 at 9:00 a.m. ET.

Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

Intellia Therapeutics

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

2 Gene-Editing Stocks to Have on Your Radar Right Now

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer and Andrew Bellinger, M.D., Ph.D., chief scientific officer and chief medical officer, will participate in a fireside chat during the Chardan Virtual 5th Annual Genetics Medicines Conference on Monday, October 4, 2021 at 11:00 a.m. ET. Dr. Kathiresan will also participate in a panel titled, “Genetic Medicines: The Ongoing Emergence of the Heart as a Target Tissue Panel” on Monday, October 4, 2021 at 3:00 p.m. ET.

Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

Verve Therapeutics Inc (NASDAQ: VERV) has reported new preclinical data from 36 non-human primates (NHPs) with its lead candidate, VERVE-101. VERVE-101 is a potential single-course gene-editing treatment for atherosclerotic cardiovascular disease (ASCVD).

Verve Therapeutics' Gene-Editing Therapy Shows Encouraging Preclinical Action In Cardiovascular Disease

Verve is a new IPO formed by world experts in cardiology and genetics.

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021

Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results

The dictionary describes the word “verve” as having energy, or vitality. It seems appropriate, then, that shares of biotech startup Verve Therapeutics, Inc. ( VERV , Financial) are up nearly $170% to $51 less than a month after its IPO at $19 a share.

Verve Therapeutics Gets Off to a Fast Start

Find out why these stocks are climbing higher.

Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money

Verve Therapeutics Inc. shares soared 68% in their trading debut Thursday, after the Massachusetts-based biotechnology company's upsized initial public offering priced above the expected range to value the company at about $832.6 million. Verve, which focuses on genetic medicines for cardiovascular disease, sold 14.04 million shares in the IPO, which priced at $19 a share, to raise $266.7 million.

Verve Therapeutics shares soar 68% in trading debut

Lyell Immunopharma

iSpecimen

The companies are Verve Therapeutics, Lyell Immunopharma, iSpecimen and Angel Oak Mortgage.

3 Biotechs Plus a Mortgage Lender Go Public Today

Verve Therapeutics Inc. is set to go public Thursday, after the Massachusetts-based biotechnology company's upsized initial public offering priced overnight above the expected range to value the company at about $832.6 million. Verve, which focuses on genetic medicines for cardiovascular disease, said it sold 14.04 million shares in the IPO, which priced at $19 a share, to raise $266.7 million.

Verve Therapeutics upsized IPO prices above the expected range

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its initial public offering of 14,035,789 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Verve from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $266.7 million. All of t

Verve Therapeutics Announces Pricing of Initial Public Offering

Verve Therapeutics has filed proposed terms for a $201 million IPO. The firm is developing treatments for hypercholesterolemia.

Verve Therapeutics Prepares $201 Million IPO

News for Verve Therapeutics Stock (VERV)